Venlafaxine and nefazodone, two pharmacologically distinct antidepressants

Bruce G. Augustin, Julie A. Cold, Michael W. Jann

Research output: Contribution to journalReview article

23 Scopus citations

Abstract

Venlafaxine, a phenylethylamine, and nefazodone, a phenylpiperazine compound, are the newest antidepressants to receive approval of the Food and Drug Administration and to be marketed in the United States. Both strongly inhibit serotonin (5-HT) reuptake; venlafaxine also inhibits norepinephrine reuptake, and nefazodone also exhibits 5-HT2-receptor antagonism. Venlafaxine inhibits the cytochrome P-450 2D6 isozyme to a lesser extent than the selective serotonin reuptake inhibitors (SSRIs) and is 27% protein bound. Structurally the drugs are unrelated to SSRIs and have some clinically important differences in side effect profiles. Nausea, headache, somnolence, and dry mouth are the most frequently reported side effects with both. Sustained hypertension was reported by a limited number of venlafaxine- treated patients.

Original languageEnglish
Pages (from-to)511-530
Number of pages20
JournalPharmacotherapy
Volume17
Issue number3
StatePublished - 1 May 1997

Fingerprint Dive into the research topics of 'Venlafaxine and nefazodone, two pharmacologically distinct antidepressants'. Together they form a unique fingerprint.

  • Cite this